XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2

Collaboration and License Agreements - Additional Information (Details) $ / shares in Units, $ in Thousands								1 Months Ended									3 Months Ended						9 Months Ended
	May 16, 2022 USD ($)	Mar. 25, 2021 USD ($) $ / shares	Feb. 14, 2021 USD ($) Program	Feb. 14, 2021 USD ($)	Apr. 29, 2020 USD ($) Unit $ / shares shares	May 31, 2018 USD ($)	Oct. 31, 2017	Jul. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020	Aug. 31, 2019 USD ($)	Sep. 30, 2018 USD ($) Antibodies	Jul. 31, 2018 USD ($) Product	May 31, 2018 USD ($) Program	Oct. 31, 2017 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 shares	Jun. 30, 2020 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	May 27, 2022 USD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue, current																	$ 22,865						$ 22,865			$ 98,209
Deferred revenue, noncurrent																	54,653						54,653			3,815
Adjustments to profit-sharing amounts									$ 20,400
Cost of revenue																	22,253		$ 7,836				140,323	$ 8,988
Receivable from collaboration																	0						0			773,079
Contract Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue																	39,998		315				52,534	169,581
Collaboration Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue																	309,145		102,398				1,483,860	107,731
License
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue																	22,289		0				22,289	0
2020 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Adjustments to profit-sharing amounts																							379,500
GSK | Accrued and Other Liabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Receivable from collaboration																	0						0			$ 773,100
2021 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reclassified deferred revenue																	51,700						51,700
Deferred revenue, noncurrent																	51,700						51,700
2020 Stock Purchase Agreement | 2020 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of common stock (in shares) | shares					6,626,027
Share purchase price per share | $ / shares					$ 37.73
Issuance of common stock					$ 250,000
Preliminary Collaboration Agreement | 2020 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of years conduct certain research and development activities under mutually agreed development plans					4 years
Increase Decrease In Research And Development Expense																	10,400		12,000				$ 24,000	49,200
Maximum percentage of right to perform details in connection with antibody product					20.00%
Termination description																							Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.
Number of units of account | Unit					4
Collaboration type and program										The collaboration is focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2 and potentially other coronaviruses (the “Antibody Program”); (2) vaccines targeting SARS-CoV-2 and potentially other coronaviruses (the “Vaccine Program”), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2 and potentially other coronaviruses (the “Functional Genomics Program”).
Preliminary Collaboration Agreement | 2020 GSK | Antibody Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of development costs					72.50%
Antibody license transaction price					$ 43,300
Total revenue																						$ 43,300
Preliminary Collaboration Agreement | 2020 GSK | Vaccine Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of development costs					27.50%
Preliminary Collaboration Agreement | 2021 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of separate programs | Program			3
Upfront payment receivable			$ 225,000	$ 225,000
Option exercise fee to be received			300,000	300,000
Preliminary Collaboration Agreement | 2021 GSK | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Pre-defined regulatory milestone payment			$ 200,000	200,000
2020 Preliminary Collaboration Agreement and Stock Purchase Agreement | 2020 GSK | ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Fair market value of the common stock issued					$ 206,700
Common stock price per share | $ / shares					$ 36.70
Premium received on sale price of common stock					$ 43,300
2021 Stock Purchase Agreement | 2021 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of common stock (in shares) | shares																					1,924,927
Issuance of common stock				$ 120,000
2021 Preliminary Collaboration Agreement and Stock Purchase Agreement | 2021 GSK | ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Fair market value of the common stock issued		$ 85,200
Common stock price per share | $ / shares		$ 52.70
Premium received on sale price of common stock		$ 34,800
2021 GSK Collaboration
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of years conduct certain research and development activities under mutually agreed development plans				3 years
Percentage of share development costs			50.00%
Percentage of share Profit and loss			50.00%
2021 GSK Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Increase Decrease In Research And Development Expense																	300		400				$ 1,300	1,300
Fixed consideration				$ 225,000
Premium paid on sale price of common stock			$ 34,800
Consideration				$ 259,800
2021 GSK Agreement | Contract Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue																				$ 168,300
2021 GSK Agreement | GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
contract revenue																	39,800
Deferred revenue																	39,800						39,800
Brii Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Increase Decrease In Research And Development Expense																	0		0				1,300	400
Termination description															Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with 30 days’ written notice (if the terminating party has not exercised an option for such program) or 180 days' notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party’s uncured material breach on 60 days’ written notice (or 30 days’ notice following failure to make payment).
Written notice to terminate licensed program if not exercise															30 days
Written notice to terminate licensed program if exercise															180 days
Written notice period to terminate licensed program for uncured material breach															60 days
Written notice period to terminate licensed program for failure to make payment															30 days
Brii Agreement | Development Programs Exercised by Vir
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Option exercise fee, high end of the range						$ 50,000									$ 50,000
Option exercise fee, low end of the range						low tens of millions
Regulatory milestone payment on licensed product, high end of the range						$ 100,000									$ 100,000
Regulatory milestone payment on licensed product, low end of the range															low tens of millions
Brii Agreement | Development Programs Exercised by Vir | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum sale milestone payment to pay						175,000									$ 175,000
Brii Agreement | Development Programs Exercised by Brii
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Option exercise fee, high end of the range						20,000									$ 20,000
Option exercise fee, low end of the range															mid-single-digit millions
Regulatory milestone payment on licensed product, high end of the range						$ 30,000									$ 30,000
Regulatory milestone payment on licensed product, low end of the range															mid-single-digit millions
Maximum aggregate sales milestone payments															$ 175,000
Range of royalty payment to be received										high-teens to high-twenties
Range of royalty payment to be paid															mid-teens to the high-twenties
Regulatory milestone payment to be received										$ 30,000
Brii Agreement | Development Programs Exercised by Brii | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum sales milestone to pay										175,000												$ 175,000
Brii Agreement | Brii Bio Parent
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum number of development program granted from Vir to Brii | Program															4
Maximum number of development program granted from Brii to Vir | Program															4
Percentage of ordinary share equal to outstanding share															9.90%
Carrying value of investment at cost																				$ 5,700
Deferred revenue								$ 2,300
Options Transaction Price								22,300
Brii Agreement | Brii Bio Parent | License
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from related parties																	22,300
Brii Agreement | Brii Bio Parent | VIR-2218
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Option exercise fee received								20,000		$ 20,000
Brii Agreement | Brii Bio
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue, noncurrent																	1,500						1,500
Royalty payment obligation expiration period after first commercial sales															10 years
Brii Agreement | Brii Bio | Development Programs Exercised by Brii
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Range of royalty payments to be received								30,000
Option exercise fee received								20,000
Brii Agreement | Brii Bio | Development Programs Exercised by Brii | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum Sales Milestone To Be Received								$ 175,000
Alnylam Agreement | Alnylam Pharmaceuticals Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty payment obligation expiration period after first commercial sales																10 years
Written notice period to terminate licensed program for uncured material breach																60 days
Written notice period to terminate licensed program for failure to make payment																30 days
Expenses incurred under agreement																	500		700				800	2,400
Written notice period for termination of licensed program																90 days
Written Notice period to terminate licensed program if under challenge																30 days
Alnylam Agreement | Alnylam Pharmaceuticals Inc | First siRNA product
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum milestone payment for achievement of specified development and regulatory																$ 190,000
Alnylam Agreement | Alnylam Pharmaceuticals Inc | Each Infectious Disease siRNA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum milestone payment for achievement of specified development and regulatory																115,000
Maximum sales milestone payment																$ 100,000
Range of tiered royalties to pay on net sales of products																high single-digits to the sub-teen double-digits
Alnylam Agreement | Alnylam Pharmaceuticals Inc | First siRNA Product HBV
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum aggregate sales milestone payment																$ 250,000
Range of tiered royalties to pay on net sales of products							The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the low double-digits to mid-teens on annual net sales of HBV products, and tiered royalties at percentages ranging from the high single-digits to the sub-teen double-digits on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets									low double-digits to mid-teens
Rockefeller Agreement | Rockefeller
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Termination description														The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on 60 days’ written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days’ written notice for the Company’s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company’s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the Rockefeller Agreement.
Written notice period to terminate agreement by company														60 days
Written notice period to terminate agreement by counterparty														90 days
Royalty obligation period from date of first commercial sale														12 years
Research and development expense under license agreement																								4,700
Rockefeller Agreement | Rockefeller | Commercialization
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Annual License Maintenance Fees														$ 1,000
Rockefeller Agreement | Rockefeller | First Infectious Disease Product
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum aggregate milestone payment for achievement of specified milestones														$ 80,300
Maximum number of products covered against milestone payment | Product														6
MedImmune Agreement | Influenza A and Influenza B
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalties payment range on net sales of licensed product													mid-single-digits to sub-teen double-digits
MedImmune Agreement | MedImmune
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of antibodies to develop | Antibodies													2
MedImmune Agreement | MedImmune | Influenza A and Influenza B
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Termination description													The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days’ notice. Either party may terminate the MedImmune Agreement for cause for the other party’s uncured material breach on 60 days’ notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on 30 days’ written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.
Written notice period to terminate licensed program for uncured material breach													60 days
Maximum aggregate milestone payment for achievement of specified milestones													$ 331,500
Written notice period for termination of licensed program													120 days
Written Notice period to terminate licensed program if under challenge													30 days
2019 Xencor Agreement | Xencor | Influenza A and HBV Research Programs
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalties payment range on net sales of licensed product												low- to mid-single-digits
Maximum aggregate development and regulatory milestone payments												$ 17,800
Maximum aggregate commercial sales milestone payments												60,000
Maximum aggregate milestone payments												155,500
2019 Xencor Agreement | Xencor | Influenza A and HBV Research Programs | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum aggregate milestone payments												$ 77,800
2019 and 2020 Xencor Agreement | Xencor
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Termination description											The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon 60 days’ written notice. Either party may terminate each agreement for the other party’s uncured material breach upon 60 days’ written notice (or 30 days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon 30 days’ written notice if any of the Company’s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.
Written notice period to terminate licensed program for uncured material breach											60 days
Written notice period to terminate licensed program for failure to make payment											30 days
Written notice period for termination of licensed program											60 days
Written Notice period to terminate licensed program if under challenge											30 days
2020 Xencor Agreement | Xencor
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalties Based on Net Sales of Licensed Products											mid-single-digits
Royalties payment expiration period											12 years
Cost of revenue																	$ 17,800		$ 6,300				$ 109,700	$ 7,200
Amendment Number One | 2020 GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contract revenue																		$ 7,000
Upfront payment receivable																									$ 7,000
Termination Agreement | WuXi Biologics
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront Payment	$ 7,000

X

- Definition

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522

+ Details

Name:	us-gaap_AccountsReceivableNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

+ Details

Name:	us-gaap_CostOfRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 25
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598

+ Details

Name:	us-gaap_DeferredIncome
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(c))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DeferredRevenueNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all investments.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.1(h))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

+ Details

Name:	us-gaap_Investments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Name:	us-gaap_RevenueFromRelatedParties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Adjustments To Profit Sharing Amounts

+ References

No definition available.

+ Details

Name:	vir_AdjustmentsToProfitSharingAmounts
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

License maintenance fees required to pay annually.

+ References

No definition available.

+ Details

Name:	vir_AnnualLicenseMaintenanceFees
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Transaction price for the Antibody License under the collaboration agreement

+ References

No definition available.

+ Details

Name:	vir_AntibodyLicenseTransactionPrice
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaboration agreement, number of separate programs agreed to collaborate.

+ References

No definition available.

+ Details

Name:	vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate
Namespace Prefix:	vir_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaboration agreement, number of units of account.

+ References

No definition available.

+ Details

Name:	vir_CollaborationAgreementNumberOfUnitsOfAccount
Namespace Prefix:	vir_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Costs and expenses for the period incurred under the collaboration agreements.

+ References

No definition available.

+ Details

Name:	vir_CollaborationAgreementRelatedCostsAndExpenses
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaboration agreement termination description.

+ References

No definition available.

+ Details

Name:	vir_CollaborationAgreementTerminationDescription
Namespace Prefix:	vir_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaboration agreement transaction price consideration.

+ References

No definition available.

+ Details

Name:	vir_CollaborationAgreementTransactionPriceConsideration
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaboration agreement, transaction price fixed consideration.

+ References

No definition available.

+ Details

Name:	vir_CollaborationAgreementTransactionPriceFixedConsideration
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaboration Type and Programs

+ References

No definition available.

+ Details

Name:	vir_CollaborationTypeAndPrograms
Namespace Prefix:	vir_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Fair market value of common stock issued.

+ References

No definition available.

+ Details

Name:	vir_FairMarketValueOfCommonStockIssued
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Increase (decrease) in research And development expense.

+ References

No definition available.

+ Details

Name:	vir_IncreaseDecreaseInResearchAndDevelopmentExpense
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Maximum aggregate commercial sales milestone payments.

+ References

No definition available.

+ Details

Name:	vir_MaximumAggregateCommercialSalesMilestonePayments
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum aggregate development and regulatory milestone payments.

+ References

No definition available.

+ Details

Name:	vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum aggregate milestone payment for achievement of specified milestones, including development, regulatory and commercial.

+ References

No definition available.

+ Details

Name:	vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum aggregate milestone payments.

+ References

No definition available.

+ Details

Name:	vir_MaximumAggregateMilestonePayments
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum aggregate milestone payment for achievement of specified annual net sales

+ References

No definition available.

+ Details

Name:	vir_MaximumAggregateSalesMilestonePayment
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum aggregate sales milestone payments.

+ References

No definition available.

+ Details

Name:	vir_MaximumAggregateSalesMilestonePayments
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum milestone payment for achievement of specified development and regulatory.

+ References

No definition available.

+ Details

Name:	vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum Number of Development Program Granted from Counterparty

+ References

No definition available.

+ Details

Name:	vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty
Namespace Prefix:	vir_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Maximum Number of Development Program Granted to Counterparty

+ References

No definition available.

+ Details

Name:	vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty
Namespace Prefix:	vir_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Maximum number of products covered against milestone payment.

+ References

No definition available.

+ Details

Name:	vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment
Namespace Prefix:	vir_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Maximum percentage of right to perform details in connection with antibody product.

+ References

No definition available.

+ Details

Name:	vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct
Namespace Prefix:	vir_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Maximum Sale Milestone Payment to Pay

+ References

No definition available.

+ Details

Name:	vir_MaximumSaleMilestonePaymentToPay
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Maximum amount of proceeds to pay upon achievement of sales milestone

+ References

No definition available.

+ Details

Name:	vir_MaximumSalesMilestonToPay
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Maximum milestone payment for achievement of specified annual net sales.

+ References

No definition available.

+ Details

Name:	vir_MaximumSalesMilestonePayment
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum sales milestone to be received.

+ References

No definition available.

+ Details

Name:	vir_MaximumSalesMilestoneToBeReceived
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Number of antibodies to develop.

+ References

No definition available.

+ Details

Name:	vir_NumberOfAntibodiesToDevelop
Namespace Prefix:	vir_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of years conduct certain research and development activities under mutually agreed development plans.

+ References

No definition available.

+ Details

Name:	vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans
Namespace Prefix:	vir_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

One time upfront payment.

+ References

No definition available.

+ Details

Name:	vir_OneTimeUpfrontPayment
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Option exercise fee consideration to be received.

+ References

No definition available.

+ Details

Name:	vir_OptionExerciseFeeConsiderationToBeReceived
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents the high end of the range of option exercise fee upon exercise of a program.

+ References

No definition available.

+ Details

Name:	vir_OptionExerciseFeeHighEndOfTheRange
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents the low end of the range of option exercise fee upon exercise of a program.

+ References

No definition available.

+ Details

Name:	vir_OptionExerciseFeeLowEndOfTheRange
Namespace Prefix:	vir_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Option exercise fee received.

+ References

No definition available.

+ Details

Name:	vir_OptionExerciseFeeReceived
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Options transaction price

+ References

No definition available.

+ Details

Name:	vir_OptionsTransactionPrice
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Percentage of development costs.

+ References

No definition available.

+ Details

Name:	vir_PercentageOfDevelopmentCosts
Namespace Prefix:	vir_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of ordinary share equal to outstanding share.

+ References

No definition available.

+ Details

Name:	vir_PercentageOfOrdinaryShareEqualToOutstandingShare
Namespace Prefix:	vir_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of share development costs.

+ References

No definition available.

+ Details

Name:	vir_PercentageOfShareDevelopmentCosts
Namespace Prefix:	vir_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Pre-defined regulatory milestone consideration receivable.

+ References

No definition available.

+ Details

Name:	vir_PreDefinedRegulatoryMilestoneConsiderationReceivable
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Premium paid on sale price of common stock.

+ References

No definition available.

+ Details

Name:	vir_PremiumPaidOnSalePriceOfCommonStock
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Premium received on sale price of common stock.

+ References

No definition available.

+ Details

Name:	vir_PremiumReceivedOnSalePriceOfCommonStock
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Profits and losses sharing percentage.

+ References

No definition available.

+ Details

Name:	vir_ProfitsAndLossesSharingPercentage
Namespace Prefix:	vir_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Range of royalty payment to be paid by counterparty.

+ References

No definition available.

+ Details

Name:	vir_RangeOfRoyaltyPaymentToBePaid
Namespace Prefix:	vir_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Range of royalty payment to be received by the company upon exercised of the development programs by counterparty.

+ References

No definition available.

+ Details

Name:	vir_RangeOfRoyaltyPaymentToBeReceived
Namespace Prefix:	vir_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Range of royalty payments to be received.

+ References

No definition available.

+ Details

Name:	vir_RangeOfRoyaltyPaymentsToBeReceived
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Range of tiered royalties to pay on annual net sales of products.

+ References

No definition available.

+ Details

Name:	vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts
Namespace Prefix:	vir_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Reclassified deferred revenue.

+ References

No definition available.

+ Details

Name:	vir_ReclassifiedDeferredRevenue
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Regulatory milestone payment on licensed product, high end of the range.

+ References

No definition available.

+ Details

Name:	vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Regulatory milestone payment on licensed product, low end of the range.

+ References

No definition available.

+ Details

Name:	vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange
Namespace Prefix:	vir_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Regulatory milestone payment to be received by the company upon exercised of the development programs by counterparty.

+ References

No definition available.

+ Details

Name:	vir_RegulatoryMilestonePaymentToBeReceived
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Research and development expense under license agreement

+ References

No definition available.

+ Details

Name:	vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Royalties payment based on net sales of licensed products.

+ References

No definition available.

+ Details

Name:	vir_RoyaltiesBasedOnNetSalesOfLicensedProducts
Namespace Prefix:	vir_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of years that royalties payment expired.

+ References

No definition available.

+ Details

Name:	vir_RoyaltiesPaymentExpirationPeriod
Namespace Prefix:	vir_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalties payment range on net sales of licensed product.

+ References

No definition available.

+ Details

Name:	vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct
Namespace Prefix:	vir_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty obligation period from date of first commercial sale.

+ References

No definition available.

+ Details

Name:	vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale
Namespace Prefix:	vir_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty payment obligation expiration period after first commercial sales.

+ References

No definition available.

+ Details

Name:	vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales
Namespace Prefix:	vir_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Upfront payment receivable.

+ References

No definition available.

+ Details

Name:	vir_UpfrontPaymentReceivable
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Written notice period for termination of licensed program.

+ References

No definition available.

+ Details

Name:	vir_WrittenNoticePeriodForTerminationOfLicensedProgram
Namespace Prefix:	vir_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Written notice period to terminate agreement by company.

+ References

No definition available.

+ Details

Name:	vir_WrittenNoticePeriodToTerminateAgreementByCompany
Namespace Prefix:	vir_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Written notice period to terminate agreement by counterparty.

+ References

No definition available.

+ Details

Name:	vir_WrittenNoticePeriodToTerminateAgreementByCounterparty
Namespace Prefix:	vir_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Written notice period to terminate licensed program for failure to make payment.

+ References

No definition available.

+ Details

Name:	vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment
Namespace Prefix:	vir_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Written notice period to terminate licensed program for uncured material breach.

+ References

No definition available.

+ Details

Name:	vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach
Namespace Prefix:	vir_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.

+ References

No definition available.

+ Details

Name:	vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge
Namespace Prefix:	vir_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Written notice to terminate licensed program following the exercise of an option for such program.

+ References

No definition available.

+ Details

Name:	vir_WrittenNoticeToTerminateLicensedProgramIfExercise
Namespace Prefix:	vir_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Written notice to terminate licensed program if not exercise.

+ References

No definition available.

+ Details

Name:	vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise
Namespace Prefix:	vir_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=vir_ContractRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=vir_CollaborationRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=vir_GlaxoWellcomeUKLimitedAndBeechamSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BalanceSheetLocationAxis=vir_AccruedLiabilitiesAndOtherLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=vir_AntibodyProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=vir_VaccineProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyOneStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKCollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=vir_DevelopmentProgramsExercisedByVirMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=vir_DevelopmentProgramsExercisedByBriiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=vir_BriiBioParentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=vir_Vir2218Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=vir_BriiBiosciencesOffshoreLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=vir_AlnylamPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=vir_FirstSiRNAProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=vir_EachInfectiousDiseaseSiRNAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=vir_FirstSiRNAProductHBVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=vir_RockefellerUniversityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=vir_CommercializationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=vir_FirstInfectiousDiseaseProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=vir_InfluenzaAAndInfluenzaBMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=vir_MedImmuneLimitedLiabilityCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=vir_XencorIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=vir_InfluenzaAAndHBVResearchProgramsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyXencorAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_AmendmentNumberOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_TerminationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=vir_WuXiBiologicsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: